An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?
There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients.
The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics.
A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care.
Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated.
These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy.
The contents of this study are solely the responsibility of the authors and do not necessarily represent the official view of the NCI, NCATS or NIH.
Compliance with Ethical Standards
This publication was made possible by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and grant number UL1TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Conflict of interest
Tanya Wildes receives research funding from Janssen and has consulted for Carevive Systems. Arti Hurria is a principal investigator for Celgene and Novartis, and a consultant for Boehringer Ingelheim Pharmaceuticals and Pieran Biosciences. Amy Zhou, Holly Holmes, Arti Hurria and Tanya Wildes declare that they have no conflicts of interest directly relevant to the content of this study.
- 1.National Cancer Institute. SEER Stat fact sheets: all cancer sites. http://seer.cancer.gov/statfacts/html/all.html.
- 2.He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population Reports, P95/16-1, An Aging World: 2015; Washington, DC: US Government Publishing Office; 2016. p. 95.Google Scholar
- 7.Deschler B, Platzbecker U, Germing U, et al. Arrangement of parameters of a geriatric and quality of life assessment in elderly patients with myelodysplastic syndromes and acute myeloid leukemia during six months of different therapeutic modalities. Haematologica. 2010;95(109):abstract no. 0464.Google Scholar
- 10.National Comprehensive Cancer Network. http://www.nccn.org/.
- 11.NCCN Chemotherapy Order Templates (NCCN Guidelines®) © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
- 12.Ettinger DS, Berger MJ, Aston J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Version 2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
- 13.Dotan E, Walter LC, Baumgartner J, et al. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®) for Older Adult Oncology V.2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.